prikaz prve stranice dokumenta Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
  Download
PDF 1.16 MB
Scientific paper - Original scientific paper
Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
Journal of Oncology, 2020 (2020); 6423936. https://doi.org/10.1155/2020/6423936
Majić, Ana; Miše, Branka Petrić; Matković, Višnja; Belac-Lovasić, Ingrid; Katić, Kristina; Canjko, Ivana; Frobe, Ana; Bajić, Žarko; Vrdoljak, Eduard

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Majić, A., Miše, B. P., Matković, V., Belac Lovasić, I., Katić, K., Canjko, I. ... Vrdoljak, E. (2020). Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study. Journal of Oncology, 2020.. doi: 10.1155/2020/6423936

Majić, Ana, et al. "Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study." Journal of Oncology, vol. 2020, 2020. https://doi.org/10.1155/2020/6423936

Majić, Ana, Branka Petrić Miše, Višnja Matković, Ingrid Belac Lovasić, Kristina Katić, Ivana Canjko, Ana Frobe, Žarko Bajić and Eduard Vrdoljak. "Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study." Journal of Oncology 2020 (2020). https://doi.org/10.1155/2020/6423936

Majić, A., et al. (2020) 'Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study', Journal of Oncology, 2020. doi: 10.1155/2020/6423936

Majić A, Miše BP, Matković V, Belac Lovasić I, Katić K, Canjko I, and sur.. Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study. Journal of Oncology [Internet]. 2020 June 20 [cited 2024 May 14];2020. doi: 10.1155/2020/6423936

A. Majić, et al., "Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study", Journal of Oncology, vol. 2020, June 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:589476. [Accessed: 14 May 2024]

Metadata
Title (english)Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
AuthorAna Majić
AuthorBranka Petrić Miše
AuthorVišnja Matković
AuthorIngrid Belac-Lovasić
AuthorKristina Katić
AuthorIvana Canjko
AuthorAna Frobe
AuthorŽarko Bajić
AuthorEduard Vrdoljak
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Oncology and Radiotherapy)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Abstract (english)
Our objective was to assess the safety and efficacy of olaparib in maintenance therapy of BRCA 1-2 mutated, platinum-sensitive, recurrent ovarian carcinoma after the partial or complete response to the second or further lines platinum-based chemotherapy in a real-world setting. We performed a multicenter, real-world observational population-based cohort study on the whole population of Croatian patients initiated to olaparib maintenance therapy between 2016 and 2020. The primary endpoints were progression-free survival and the discontinuation of treatment because of adverse events. We enrolled the total population of 69 patients with the median (interquartile range; IQR) age of 53 (48–59), 56 (81%) of them with BRCA1 mutation. The median (IQR) follow-up was 16 (9–25) months. Treatment had to be discontinued because of toxicity in 2 (3%) and temporarily interrupted in 14 (20%), while dose was reduced because of toxicity in 18 (26%) of patients. Toxicity of any grade was observed in 61 (88%) patients and toxicity of grade 3 or 4 in 12 (17%). Median progression-free survival was 21 (95% CI 16-not calculable) months from the introduction of olaparib, and the median overall survival was not reached. Our study confirmed efficacy and safety of olaparib as the maintenance therapy of BRCA 1-2 mutated, platinum-sensitive, recurrent ovarian carcinoma. We observed the real-world efficacy and safety comparable to those observed in the randomized controlled trials. We found the interesting observation of better efficacy of 300 mg tablets, compared to 400 mg capsules, an issue that should be addressed on much larger real-world populations.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleJournal of Oncology
Numberingvol. 2020, 6423936
p-ISSN1687-8450
e-ISSN1687-8469
DOIhttps://doi.org/10.1155/2020/6423936
URN:NBNurn:nbn:hr:184:589476
Publication2020-06-20
Document URLhttps://www.hindawi.com/journals/jo/2020/6423936/
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2020-11-10 20:31:47